We are live on ! Find out more
AVLSA

Atlas Venture Life Science Advisors Portfolio holdings

AUM $790M
1-Year Est. Return 223.66%
This Fund
S&P 500
This Quarter Est. Return
+28.09%
1 Year Est. Return
+223.66%
3 Year Est. Return
+485.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.08B
AUM Growth
+$129M
Cap. Flow
-$40.8M
Cap. Flow %
-3.78%
Top 10 Hldgs %
98.6%
Holding
15
New
–
Increased
–
Reduced
3
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$20M
2
REPL icon
Replimune Group
REPL
+$18.9M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$1.67M
4
SPRO icon
Spero Therapeutics
SPRO
+$178K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
1
Dyne Therapeutics
DYN
$4.7B
$288M 26.71%
8,020,136
– –
KYMR icon
2
Kymera Therapeutics
KYMR
$8.51B
$232M 21.48%
4,896,462
-453,960
-8% -$20M
THRD
3
DELISTED
Third Harmonic Bio
THRD
$148M 13.7%
10,907,859
– –
IRON icon
4
Disc Medicine
IRON
$2.96B
$123M 11.43%
2,509,456
– –
QTTB icon
5
Q32 Bio
QTTB
$466M
$93.3M 8.65%
2,092,106
– –
DAWN
6
DELISTED
Day One Biopharmaceuticals
DAWN
$89.6M 8.3%
6,430,257
– –
KRRO icon
7
Korro Bio
KRRO
$150M
$38M 3.52%
1,137,149
– –
GBIO
8
DELISTED
Generation Bio
GBIO
$20.5M 1.9%
827,948
– –
VIGL
9
DELISTED
Vigil Neuroscience
VIGL
$19.8M 1.84%
5,836,874
– –
TECX
10
Tectonic Therapeutic
TECX
$529M
$11.5M 1.06%
378,447
– –
IMA
11
ImageneBio Inc
IMA
$63M
$8.68M 0.8%
418,182
– –
JBIO
12
Jade Biosciences
JBIO
$1.2B
$3.76M 0.35%
51,407
– –
DNTH icon
13
Dianthus Therapeutics
DNTH
$5.84B
$2.11M 0.2%
76,979
-60,000
-44% -$1.67M
SPRO icon
14
Spero Therapeutics
SPRO
$67.7M
$540K 0.05%
402,885
-132,451
-25% -$178K
REPL icon
15
Replimune Group
REPL
$941M
– –
-2,098,300
Closed -$18.9M

Similar funds

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
AT
Avenir Tech Hong Kong $790M AUM 17.91% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
VH
V3 Holding Rye, New York $789M AUM 459.57% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return
VCM
Vision Capital Management Portland, Oregon $792M AUM 18.17% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return

Atlas Venture Life Science Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Atlas Venture Life Science Advisors held 15 positions worth $1.08B, up 14% from $950M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Atlas Venture Life Science Advisors withdrew a net $40.8M in Q3 2024, closing 1 position and reducing 3 holdings. Its most notable exit was Replimune Group, an estimated $18.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Atlas Venture Life Science Advisors's biggest Q3 2024 reduction was Kymera Therapeutics, cutting an estimated $20M.
  • Atlas Venture Life Science Advisors fully exited Replimune Group in Q3 2024, selling an estimated $18.9M.
  • Atlas Venture Life Science Advisors's ten largest holdings make up 99% of its $1.08B portfolio in Q3 2024.
  • Atlas Venture Life Science Advisors opened 0 new positions and closed 1 in Q3 2024.
  • Atlas Venture Life Science Advisors's portfolio value rose 14% quarter-over-quarter to $1.08B.

Based on Atlas Venture Life Science Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.